Patents by Inventor Tomohisa Watanabe
Tomohisa Watanabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10092634Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: GrantFiled: September 9, 2013Date of Patent: October 9, 2018Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20180244903Abstract: In a flame retardant resin composition containing a polyolefin resin, a silicone-based compound blended at a ratio of 1.5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, and an inorganic flame retardant blended at a ratio of 5 parts by mass or more and 40 parts by mass or less relative to 100 parts by mass of the polyolefin resin, the decomposition onset temperature of the inorganic flame retardant is lower than the decomposition onset temperature of the silicone-based compound.Type: ApplicationFiled: April 26, 2018Publication date: August 30, 2018Applicant: FUJIKURA LTD.Inventors: Haruka KOHRI, Masayuki IWATA, Tomohisa WATANABE
-
Publication number: 20180222954Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.Type: ApplicationFiled: March 22, 2018Publication date: August 9, 2018Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
-
Publication number: 20180166186Abstract: Disclosed is a flame retardant resin composition containing a polyolefin resin, a silicone compound, a fatty acid containing compound, calcium carbonate, and a triazine ring containing hindered amine compound. In this composition, relative to 100 parts by mass of the polyolefin resin, the silicone compound is blended at a ratio of 1.5 parts by mass or more and 10 parts by mass the fatty acid containing compound is blended at a ratio of 3 parts by mass or more and 20 parts by mass, the calcium carbonate is blended at a ratio of 10 parts by mass or more and less than 120 parts by mass, the triazine ring containing hindered amine compound is blended at a ratio of 0.05 part by mass or more and less than 10 parts by mass, and the triazine ring containing hindered amine compound includes an oxygen atom.Type: ApplicationFiled: June 23, 2016Publication date: June 14, 2018Applicant: FUJIKURA LTD.Inventors: Haruka Kohri, Shoichiro Nakamura, Tomohisa Watanabe
-
Patent number: 9982119Abstract: In a flame retardant resin composition containing a polyolefin resin, a silicone-based compound blended at a ratio of 1.5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, and an inorganic flame retardant blended at a ratio of 5 parts by mass or more and 40 parts by mass or less relative to 100 parts by mass of the polyolefin resin, the decomposition onset temperature of the inorganic flame retardant is lower than the decomposition onset temperature of the silicone-based compound.Type: GrantFiled: December 3, 2014Date of Patent: May 29, 2018Assignee: FUJIKURA LTD.Inventors: Haruka Kohri, Masayuki Iwata, Tomohisa Watanabe
-
Patent number: 9982118Abstract: Provided is a flame retardant resin composition including a base resin, calcium carbonate particles that are incorporated at a proportion of 10 parts by mass or more relative to 100 parts by mass of the base resin, a silicone-based compound that is incorporated at a proportion of more than 1 part by mass relative to 100 parts by mass of the base resin, and a fatty acid-containing compound that is incorporated at a proportion of more than 3 parts by mass relative to 100 parts by mass of the base resin. The average particle size of the calcium carbonate particles is 0.7 ?m or larger.Type: GrantFiled: April 25, 2014Date of Patent: May 29, 2018Assignee: FUJIKURA LTD.Inventors: Masayuki Iwata, Tomohisa Watanabe, Kazuya Hoshino
-
Patent number: 9975935Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.Type: GrantFiled: August 4, 2016Date of Patent: May 22, 2018Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura, Yoichi Furukawa
-
Publication number: 20180079791Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.Type: ApplicationFiled: July 31, 2015Publication date: March 22, 2018Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: TAKUYA TSUNODA, RYUJI OSAWA, SACHIKO YAMASHITA, TOMOHISA WATANABE
-
Patent number: 9896492Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.Type: GrantFiled: June 29, 2016Date of Patent: February 20, 2018Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20180042954Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.Type: ApplicationFiled: July 31, 2015Publication date: February 15, 2018Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: TAKUYA TSUNODA, RYUJI OSAWA, SACHIKO YAMASHITA, TOMOHISA WATANABE, TETSURO HIKICHI
-
Patent number: 9849166Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.Type: GrantFiled: July 6, 2016Date of Patent: December 26, 2017Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Publication number: 20170333476Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.Type: ApplicationFiled: July 31, 2015Publication date: November 23, 2017Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Takuya TSUNODA, RYUJI OSAWA, SACHIKO YAMASHITA, TOMOHISA WATANABE, TETSURO HIKICHI
-
Publication number: 20170335198Abstract: Disclosed is a flame retardant resin composition comprising a polyolefin resin, calcium carbonate particles blended at a ratio of 5 pts. mass to 80 pts. mass, aluminum hydroxide blended at a ratio of 50 pts. mass to 125 pts. mass, a silicone-based compound blended at a ratio of more than 1 pt. mass and 10 pts. mass or less, a fatty acid-containing compound blended at a ratio of 3 pts. mass to 20 pts. mass, and a zinc-containing inorganic compound blended at a ratio of 1 pt. mass to 7 pts. mass, all relative to 100 pts. mass of the polyolefin resin. In the flame retardant resin composition, the calcium carbonate particles and the aluminum hydroxide are blended in total at a ratio of 55 pts. mass to 130 pts. mass relative to 100 pts. mass of the polyolefin resin.Type: ApplicationFiled: November 20, 2015Publication date: November 23, 2017Applicant: FUJIKURA LTD.Inventors: Haruka Kohri, Shoichiro Nakamura, Tomohisa Watanabe
-
Patent number: 9745343Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.Type: GrantFiled: July 21, 2015Date of Patent: August 29, 2017Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20170198010Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.Type: ApplicationFiled: January 23, 2017Publication date: July 13, 2017Inventors: Yusuke NAKAMURA, Takuya TSUNODA, Ryuji OSAWA, Sachiko YOSHIMURA, Tomohisa WATANABE, Gaku NAKAYAMA
-
Patent number: 9597382Abstract: Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, provided such modified versions retain the requisite CTL inducibility of the original sequences.Type: GrantFiled: March 11, 2014Date of Patent: March 21, 2017Assignee: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Patent number: 9585948Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.Type: GrantFiled: July 27, 2015Date of Patent: March 7, 2017Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Publication number: 20170051208Abstract: Disclosed is a flame retardant resin composition containing a base resin containing a polyolefin based compound, a silicone based compound, a fatty acid metal salt, a flame retardant agent consisting of at least one kind selected from the group consisting of calcium carbonate particles and silicate compound particles, a hindered phenol based compound, and a hindered amine based compound. In the composition, the silicone based compound is blended at a ratio of 0.1 part by mass or more and 10 parts by mass or less relative to 100 parts by mass of the base resin, the fatty acid metal salt is blended at a ratio of 0.1 part by mass or more and 20 parts by mass or less relative to 100 parts by mass of the base resin, the flame retardant agent is blended at a ratio of 5 parts by mass or more and 200 parts by mass or less relative to 100 parts by mass of the base resin, the hindered phenol based compound is blended at a ratio of 0.Type: ApplicationFiled: April 22, 2015Publication date: February 23, 2017Applicant: FUJIKURA LTD.Inventors: Masayuki IWATA, Tomohisa WATANABE
-
Publication number: 20170051136Abstract: In a flame retardant resin composition containing a polyolefin resin, a silicone-based compound blended at a ratio of 1.5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, a fatty acid containing compound blended at a ratio of 5 parts by mass or more and 20 parts by mass or less relative to 100 parts by mass of the polyolefin resin, and an inorganic flame retardant blended at a ratio of 5 parts by mass or more and 40 parts by mass or less relative to 100 parts by mass of the polyolefin resin, the decomposition onset temperature of the inorganic flame retardant is lower than the decomposition onset temperature of the silicone-based compound.Type: ApplicationFiled: December 3, 2014Publication date: February 23, 2017Applicant: FUJIKURA LTD.Inventors: Haruka KOHRI, Masayuki IWATA, Tomohisa WATANABE
-
Publication number: 20160368958Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.Type: ApplicationFiled: June 29, 2016Publication date: December 22, 2016Inventors: Yusuke NAKAMURA, Takuya TSUNODA, Ryuji OHSAWA, Sachiko YOSHIMURA, Tomohisa WATANABE